Ervicogenic Headache (CEH)NCT07068451
Greater Occipital Nerve Block Alone Versus Dual Nerve Block in Cervicogenic Headache and Occipital Neuralgia
A study testing Greater Occipital Nerve Block (GONB) and Combined Greater and Lesser Occipital Nerve Block (GONB + LONB) in people with Ervicogenic Headache (CEH) and Occipital Neuralgia (ON), run by Tishreen University Hospital at 1 site in Syria.
Trial summary
This study looked at two types of nerve block injections used to treat people with cervicogenic headache (CEH) and occipital neuralgia (ON)-two painful conditions that often cause pain at the back of the head and neck. The injections target nerves in the upper neck that may be causing the pain. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Ervicogenic Headache (CEH), Occipital Neuralgia (ON)
- What is being tested?
- Greater Occipital Nerve Block (GONB) and Combined Greater and Lesser Occipital Nerve Block (GONB + LONB)
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 160 participants
- Where
- 1 siteSyria
- Study dates
- 1 Jan 2020to 1 Apr 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
None listed.
Who cannot join
- Previous nerve block or other interventional procedures for headache
- Use of systemic corticosteroids within the past 3 months
- Known allergy to lidocaine or other amide-type local anesthetics
- Evidence of secondary causes of headache on imaging (e.g., tumor, infection)
- Pregnancy or breastfeeding
- Active infection at the injection site
- Coagulopathy or use of anticoagulant therapy
- Significant psychiatric or neurological comorbidities interfering with study participation
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Prospective Randomized Study Comparing Greater Occipital Nerve Block Alone Versus Dual Nerve Blockade in the Management of Cervicogenic Headache and Occipital Neuralgia
This study looked at two types of nerve block injections used to treat people with cervicogenic headache (CEH) and occipital neuralgia (ON)-two painful conditions that often cause pain at the back of the head and neck. The injections target nerves in the upper neck that may be causing the pain.
The researchers compared:
One nerve injection (greater occipital nerve block, or GONB), versus
Two nerve injections (GONB plus lesser occipital nerve block, or LONB).
- Being tested
- Greater Occipital Nerve Block (GONB), Combined Greater and Lesser Occipital Nerve Block (GONB + LONB)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Greater Occipital Nerve Block (GONB)Procedure or surgery
Also called Drug: Lidocaine 2%
A landmark-guided injection of 1 mL of 2% lidocaine administered at the anatomical location of the greater occipital nerve (GON) to treat cervicogenic headache and occipital neuralgia. Performed without corticosteroids or imaging guidance.
Combined Greater and Lesser Occipital Nerve Block (GONB + LONB)Procedure or surgery
Also called Drug: Lidocaine 2%
Two landmark-guided injections of 1 mL of 2% lidocaine each at the anatomical locations of the greater and lesser occipital nerves. Performed without corticosteroids or imaging, targeting broader nerve involvement in cervicogenic headache and occipital neuralgia.
| Study group | Role | What they receive |
|---|---|---|
| GONB Alone | Experimental | Patients received a single injection of 1 mL of 2% lidocaine at the greater occipital nerve using a landmark-guided technique. Receives: Procedure: Greater Occipital Nerve Block (GONB) |
| GONB + LONB (Dual Block) | Experimental | Patients receive two injections of 1 mL of 2% lidocaine each at the greater and lesser occipital nerves using a landmark-guided technique. Receives: Procedure: Combined Greater and Lesser Occipital Nerve Block (GONB + LONB) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in pain intensity measured by the Visual Analog Scale (VAS)
ain intensity was assessed using a 10-point Visual Analog Scale (VAS), with 0 indicating no pain and 10 indicating the worst pain imaginable. VAS scores were recorded at baseline and follow-up visits.
Measured: Baseline, 24 hours, 3 weeks, and 3 months post-intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2025
- Study start1 Jan 2020
- Primary completion1 Apr 2023
- Study completion1 Apr 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ervicogenic Headache (CEH)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 160 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tishreen University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ali Hammed, Tishreen University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07068451
- Sponsor's protocol ID
- N/2020-31
- Status last verified
- Jul 2025
- First submitted
- 26 Jun 2025
- Last updated
- 16 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Randomized Study Comparing Greater Occipital Nerve Block Alone Versus Dual Nerve Blockade in the Management of Cervicogenic Headache and Occipital Neuralgia
- ClinicalTrials.gov ID
- NCT07068451
- Acronym / sponsor ID
- N/2020-31
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 160 participants (actual)
- Lead sponsor
- Tishreen University HospitalUniversity, hospital or other
- Study start
- 1 Jan 2020 (actual)
- Primary completion
- 1 Apr 2023 (actual)
- Study completion
- 1 Apr 2023 (actual)
- First posted
- 16 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study looked at two types of nerve block injections used to treat people with cervicogenic headache (CEH) and occipital neuralgia (ON)-two painful conditions that often cause pain at the back of the head and neck. The injections target nerves in the upper neck that may be causing the pain.
The researchers compared:
One nerve injection (greater occipital nerve block, or GONB), versus
Two nerve injections (GONB plus lesser occipital nerve block, or LONB).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| GONB Alone | Experimental | Procedure: Greater Occipital Nerve Block (GONB)Patients received a single injection of 1 mL of 2% lidocaine at the greater occipital nerve using a landmark-guided technique. |
| GONB + LONB (Dual Block) | Experimental | Procedure: Combined Greater and Lesser Occipital Nerve Block (GONB + LONB)Patients receive two injections of 1 mL of 2% lidocaine each at the greater and lesser occipital nerves using a landmark-guided technique. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (0 listed)
Key exclusion criteria (8 listed)
- Previous nerve block or other interventional procedures for headache
- Use of systemic corticosteroids within the past 3 months
- Known allergy to lidocaine or other amide-type local anesthetics
- Evidence of secondary causes of headache on imaging (e.g., tumor, infection)
- Pregnancy or breastfeeding
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Greater Occipital Nerve Block (GONB)Also: Drug: Lidocaine 2%A landmark-guided injection of 1 mL of 2% lidocaine administered at the anatomical location of the greater occipital nerve (GON) to treat cervicogenic headache and occipital neuralgia. Performed without corticosteroids or imaging guidance. | Procedure or surgery | GONB Alone |
| Combined Greater and Lesser Occipital Nerve Block (GONB + LONB)Also: Drug: Lidocaine 2%Two landmark-guided injections of 1 mL of 2% lidocaine each at the anatomical locations of the greater and lesser occipital nerves. Performed without corticosteroids or imaging, targeting broader nerve involvement in cervicogenic headache and occipital neuralgia. | Procedure or surgery | GONB + LONB (Dual Block) |
Primary outcome
Change in pain intensity measured by the Visual Analog Scale (VAS)
Time frame: Baseline, 24 hours, 3 weeks, and 3 months post-intervention
ain intensity was assessed using a 10-point Visual Analog Scale (VAS), with 0 indicating no pain and 10 indicating the worst pain imaginable. VAS scores were recorded at baseline and follow-up visits.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2025.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Greater Occipital Nerve Block (GONB) and Combined Greater and Lesser Occipital Nerve Block (GONB + LONB) in people with Ervicogenic Headache (CEH) and Occipital Neuralgia (ON), run by Tishreen University Hospital at 1 site in Syria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Syria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in pain intensity measured by the Visual Analog Scale (VAS) (time frame: Baseline, 24 hours, 3 weeks, and 3 months post-intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2025.